Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Anti-PD1, CTLA-4 Immunotherapy-Related Neurotoxicities ‘Not Uncommon’ in Patients With Melanoma

November 7, 2016
By Bryant Furlow
Article

Immune checkpoint inhibitor-related neurotoxicities are more frequent in clinical practice than clinical trials.

Immune checkpoint inhibitor-related neurotoxicities are more frequent in clinical practice than clinical trials-particularly among patients receiving ipilimumab (Yervoy) plus nivolumab (Opdivo) combination therapy (ipi+nivo), according to a retrospective single-institution cohort study reported online in the Annals of Oncology.

“Neurologic toxicity is not uncommon, and may be more frequent in patients treated with combination ipi+nivo,” reported coauthor James Larkin, MD, of the Royal Marsden Hospital in London, and colleagues.

“A prompt and considered approach is required to optimize outcomes in this group of patients,” they concluded. “There is a risk of neurological irAEs [immunotherapy-related adverse events] at any stage throughout the course of treatment with immune-checkpoint agents, however presentations within the first four months predominated in our cohort (8/10, 80%).”

Small numbers prevented “any definitive statements,” but findings from the review suggest the possibility that neurotoxicity might predict treatment response, the team noted.

Immune checkpoint blockade with anti-PD1 and anti-CTLA-4 antibodies has “greatly improved” survival among patients with advanced melanoma and previously published clinical trial data suggests a cumulative neurotoxicity incidence of less than 1% among patients with melanoma receiving ipilimumab, nivolumab, or pembrolizumab (Keytruda) monotherapy, the researchers reported.

But an emerging literature of case reports suggests that neurotoxicities might be more frequently associated with these immunotherapy agents than was initially believed, they noted.

The coauthors therefore reviewed medical records for 352 patients treated with immune checkpoint inhibitors between 2010 and 2015 at the Royal Marsden Hospital in London, including ipilimumab, nivolumab, or pembrolizumab monotherapy, or combination ipi+nivo therapy.

Among these patients, 2.8% overall experienced neurotoxicities of the central and peripheral nervous systems, ranging from grade 1 to grade 4 in severity. However, patients treated with combination ipilimumab plus nivolumab experienced a much higher neurological toxicities rate of 14%, the authors reported.

Examples of recorded neurotoxicities included peripheral neuropathy, phrenic neuropathy, bulbar palsy, sensory deficits such as the loss of fine touch sensations, pain, exertional dyspnea, inspiratory muscle weakness, and lumbosacral plexopathy.

“Our report presents several cases of neurological toxicity that do not neatly fit the characteristics of ‘typical’ neurological syndromes,” the researchers noted. “Both peripheral and central nervous systems may be affected and there does not appear to be a clear predominance of one over the other, although in our cohort the peripheral nervous system was more commonly impacts (70% versus 30% of cases).”

In some cases, neurotoxicity might have resulted from neuronal microvessel inflammation, and in some cases edema, they noted. The study team did not include dysgeusia (e.g., rancid or metallic taste sensations) as a reportable neurotoxicity in their records review.

Most immune checkpoint-related neurotoxicities “can be effectively reversed with corticosteroids,” the authors noted, although the cautioned that some patients did not respond to steroids. Among the five of these patients who were treated with corticosteroids, three responded well, the team noted. Six of the 10 patients with neurotoxicity had recovered fully at a median follow-up of 26.7 months.

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Experts on myeloma
Related Content

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

FDA Lifts Hold on IFx-2.0 in Advanced/Metastatic Merkel Cell Carcinoma

Roman Fabbricatore
June 9th 2025
Article

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.


OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.


No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

Kristi Rosa
June 3rd 2025
Article

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.


On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.


Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma

Roman Fabbricatore
June 1st 2025
Article

Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.


No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.

Melphalan/Hepatic Delivery System Demonstrates Benefit in Uveal Melanoma

Roman Fabbricatore
May 4th 2025
Article

No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.

Related Content

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

FDA Lifts Hold on IFx-2.0 in Advanced/Metastatic Merkel Cell Carcinoma

Roman Fabbricatore
June 9th 2025
Article

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.


OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.


No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

Kristi Rosa
June 3rd 2025
Article

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.


On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.


Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma

Roman Fabbricatore
June 1st 2025
Article

Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.


No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.

Melphalan/Hepatic Delivery System Demonstrates Benefit in Uveal Melanoma

Roman Fabbricatore
May 4th 2025
Article

No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.